Results 241 to 250 of about 38,144 (289)
Some of the next articles are maybe not open access.
Injectable opioid agonist treatment: An evolutionary concept analysis
Research in Nursing & Health, 2021AbstractCanada is currently in the midst of an overdose crisis. With new and innovative approaches desperately needed, injectable opioid agonist treatment (iOAT) should be considered as an integral treatment option to prevent even more fatalities. These programs provide injectable diacetylmorphine or hydromorphone to clients with severe opioid use ...
Marlene Haines, Patrick O'Byrne
openaire +2 more sources
Opioid agonist treatment for people who are dependent on pharmaceutical opioids
Cochrane Database of Systematic Reviews, 2022There are ongoing concerns regarding pharmaceutical opioid-related harms, including overdose and dependence, with an associated increase in treatment demand. People dependent on pharmaceutical opioids appear to differ in important ways from people who use heroin, yet most opioid agonist treatment research has been conducted in people who use heroin ...
Suzanne, Nielsen +2 more
openaire +2 more sources
Pharmacological treatment for depression during opioid agonist treatment for opioid dependence
Cochrane Database of Systematic Reviews, 2010Lifetime prevalence of depression in subjects with opioid dependence is higher than in the general population (44-54% versus 16%) and represents a risk factor for morbidity and mortality. For patients on opioid agonist treatment, current prevalence rates of depression ranges between 10 and 30%, influencing negatively the outcome of the treatment.To ...
Pier Paolo, Pani +4 more
openaire +2 more sources
Agonist treatment in opioid use: Advances and controversy
Asian Journal of Psychiatry, 2012Opioid dependence is a chronic relapsing condition which requires comprehensive care; pharmacological agents form the mainstay of its long term treatment. The two most popular approaches are the harm reduction method using agonists and the complete abstinence method using antagonists.
Biju, Viswanath +3 more
openaire +2 more sources
Opioid Agonist Treatment Recipients within Criminal Justice-Involved Populations
Substance Use & Misuse, 2022Background: In 2014, nearly 2.5 million Americans had a substance use disorder for opioids (e.g., prescription pain medication or heroin) with over half estimated to have had prior contact with the criminal justice system. Despite strong evidence that opioid agonist treatment (OAT) is effective in reducing overdose, increasing treatment retention, and ...
Wendy P. Guastaferro +3 more
openaire +2 more sources
Journal of Substance Abuse Treatment, 2014
The New Jersey Medication Assisted Treatment Initiative (NJ-MATI) sought to reduce barriers to treatment by providing free, opioid agonist treatment (OAT, methadone or buprenorphine) via mobile medication units (MMUs). To evaluate barriers to OAT, logistic regression was used to compare opioid dependent patients enrolled in NJ-MATI to those entering ...
Gerod, Hall +9 more
openaire +2 more sources
The New Jersey Medication Assisted Treatment Initiative (NJ-MATI) sought to reduce barriers to treatment by providing free, opioid agonist treatment (OAT, methadone or buprenorphine) via mobile medication units (MMUs). To evaluate barriers to OAT, logistic regression was used to compare opioid dependent patients enrolled in NJ-MATI to those entering ...
Gerod, Hall +9 more
openaire +2 more sources
Nasal Opioid Agonist Treatment in Patients with Severe Opioid Dependence: A Case Series
European Addiction Research, 2021<b><i>Introduction:</i></b> Opioid agonist treatment (OAT) is the first-line treatment for opioid dependence. Currently available OAT options comprise oral (methadone and morphine) and sublingual (buprenorphine) routes of administration.
Marc, Vogel +9 more
openaire +2 more sources
Chronic Agonist Treatment Converts Antagonists into Inverse Agonists at δ-Opioid Receptors
The Journal of Pharmacology and Experimental Therapeutics, 2002In cellular models, chronic exposure to mu-opioid agonists converts antagonists into inverse agonists at mu-receptors. Such adaptations could contribute to the development of tolerance and/or dependence. To determine whether delta-receptors respond similarly, or whether this adaptation is unique for mu-receptors, this study examined the effects of ...
Jing-Gen, Liu, Paul L, Prather
openaire +2 more sources